SS 05 - Lung 1: NSCLC Locally Advanced and Oligometastatic

Presentations

• 02:30pm - 02:40pm PT

  Mid-Treatment ctDNA to Predict Outcomes in Stage IIB-IIIC NSCLC Treated with MRI-Adapted Chemoradiation

  Speaker: Ayesha Hashmi, MD - Mayo Clinic Alix School of Medicine, Rochester
• 02:40pm - 02:50pm PT

  Fatal Pulmonary Hemorrhage in Patients Treated with Hypofractionated RT for Stage II-III NSCLC

  Speaker: Saskia Cooke, MD - Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam
• 02:50pm - 03:00pm PT

  Sequential Chemo-Immunotherapy plus Optimized Thoracic Radiotherapy vs. Standard Thoracic Radiotherapy for Elderly and/ or Frail Stage III Non-Small-Cell Lung Cancer: A Randomized Open-Label Controlled Trial of iLCC-3

  Speaker: Wei-Xiang Qi, MD, RT - Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
• 03:00pm - 03:10pm PT

  High-Dimensional Immunophenotyping of Patients with Localized Non-Small Cell Lung Cancer (NSCLC) Reveals Distinct Immune Cell Subsets Predictive of Disease-Free Survival (DFS) in AFT-16 and LCMC3 Phase II Immunotherapy Clinical Trials

  Speaker: Nicholas Eustace, MD, PhD - City of Hope National Medical Center, Duarte
• 03:10pm - 03:20pm PT

  Gut Microbiota Predictive of Consolidation Immunotherapy Efficacy and Toxicity after Chemoradiotherapy in Lung Cancer

  Speaker: Yitong Li, MD - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy, Beijing
• 03:20pm - 03:30pm PT

  Consolidative Radiotherapy with Osimertinib in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: Long-Term Local and Intracranial Control Results from a Phase II Trial

  Speaker: Sagus Sampath, MD - City of Hope Medical Center, Duarte
• 03:30pm - 03:40pm PT

  First-Line EGFR-TKIs Combined with Primary-Focus Radiotherapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): A Real-World Retrospective Study

  Speaker: Yan Li, MD - West China Hospital of Sichuan University, Chengdu